Literature DB >> 3276289

Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.

C J Rodenburg1, I A Koelma, M Nap, G J Fleuren.   

Abstract

The monoclonal antibody RAP 5 immunoreactive with the ras gene product p21 was used in an immunohistochemical study of 57 patients with advanced ovarian cancer and in 28 normal ovaries. The pattern of the staining of various tumor specimens was similar to the germinal epithelium of normal ovaries, whereas the intensity of staining was more enhanced in carcinomas than in normal ovaries. However, we found a lack of correlation among staining intensity of RAP 5 and the histologic type, the histologic grade, the ploidy class, and the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276289

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

Authors:  P A van Dam; I B Vergote; D G Lowe; J V Watson; P van Damme; J C van der Auwera; J H Shepherd
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

2.  C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy.

Authors:  S V Polacarz; N A Hey; T J Stephenson; A S Hill
Journal:  J Clin Pathol       Date:  1989-02       Impact factor: 3.411

3.  Prognostic significance of ras/p21 alterations in human ovarian cancer.

Authors:  G Scambia; V Masciullo; P Benedetti Panici; M Marone; G Ferrandina; N Todaro; A Bellacosa; S K Jain; G Neri; A Piffanelli; S Mancuso
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.

Authors:  G Scambia; L Catozzi; P Benedetti Panici; G Ferrandina; G Almadori; G Paludetti; G Cadoni; M Distefano; A Piffanelli; S Mancuso
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.